Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)

Shots:

• Leo Pharma to invest $70M as equity investment in Pelle with R&D support to initiate P-III trial for Patidegib globally. Leo Pharma has an option to acquire Pelle, in all stock transaction
• If Leo exercises its option Pelle to receive $690M as total deal value with milestones and royalties on sales. The P-III trial for Patidegib is expected to initiate in Q1’19
• Patidegib is a topical gel, received FDA’s Breakthrough Therapy & Orphan Drug Designation, for the treatment of Gorlin Syndrome

Click here to read full press release/ article | Ref: Leo Pharma | Image: Business Wire